Abstract Nicotinic acetylcholine receptors (nAChRs) are pentameric transmembrane proteins that belong to the cysloop ligand-gated ion channel family. These receptors are widely expressed in the brain and implicated in the pathophysiology of many neurological conditions, including Alzheimer's disease (AD), where typical symptoms include the loss of cognitive function and dementia. The presence of extracellular neuritic plaques composed of β amyloid (Aβ 1-42 ) peptide is a characteristic feature of AD. Desformylflustrabromine (dFBr) is a positive allosteric modulator (PAM) for α4β2 nAChRs since it increases peak ACh responses without inducing a response on its own. Previously, the effect of dFBr on the α2β2 nAChR subtype was not known. The action of dFBr was tested on α2β2 receptors expressed in Xenopus oocytes. It was found that dFBr is also a PAM for the α2β2 receptor. Next we tested whether dFBr had any effect on the previously known block of both the α4β2 and α2β2 receptors by Aβ 1-42 . We found that the functional blockade of AChinduced currents in oocytes expressing α4β2 and α2β2 receptors by Aβ 1-42 was prevented by dFBr. We conclude that dFBr is a positive allosteric modulator for both α4β2 and α2β2 subtypes of nAChRs and that it also relieves the blockade of these receptors by Aβ 1-42 . This study demonstrates that PAMs for the non-α7 nAChRs have the potential to develop into clinically applicable drugs for AD and other disorders.
Introduction
Nicotinic acetylcholine receptors (nAChRs) are cys-loop ligand-gated ion channels activated by the neurotransmitter acetylcholine (ACh) and are distributed throughout the peripheral and central nervous system (Gay and Yakel 2007) . The main neuronal subtypes of nAChRs which are widely expressed in the brain are the α7 and the α4β2 receptors (Whiting et al. 1987; Flores et al. 1992; Gopalakrishnan et al. 1996; Lindstrom 1996; Lindstrom et al. 1996; Liu et al. 2009 ). Dysfunction of nAChRs is thought to be involved in various neurodegenerative disorders, including but not limited to Alzheimer's disease (AD; Jones et al. 1999) . A clear pathological feature of AD is the presence of amyloid plaques comprised of the β-amyloid peptide (Aβ ) and neurofibrillary tangles formed by aggregates of hyperphosphorylated tau protein (Schmechel et al. 1993; Nathan et al. 1994; Huang et al. 2001) . Severe functional loss of the cholinergic system in the basal forebrains of patients suffering from AD has been reported (Perry et al. 1986 ). In advanced cases of AD, cholinergic neurons are lost and the number of nAChRs is reduced in the hippocampus and cortex (Coyle et al. 1983) .
Aβ has been shown to directly affect nAChR function; however, there are conflicting reports of either activation or inhibition of various subtypes of nAChRs by Aβ . For example, it was first reported that Aβ 1-42 blocked whole cell and single channel native non-α7 nAChR-mediated currents in CA1 stratum radiatum inter-neurons in rat hippocampal slices, while the α7 receptors were less affected by Aβ 1-42 (Pettit et al. 2001) . Consistent with this, heteromeric α4β2 or α2β2 subtype of nAChRs expressed in either SH-EP1 cells or Xenopus oocytes were also blocked by Aβ 1-42 (Wu et al. 2004; Lamb et al. 2005) . Other studies have shown that Aβ 1-42 blocked α7 receptors in cultured rat hippocampal neurons , or in Xenopus oocytes expressing human α7 receptors (Grassi et al. 2003) . Recently, it was shown that in cultured rat basal forebrain cholinergic neurons, the α7-containing receptors, which appeared to be heteromeric α7β2 receptors, had high sensitivity to blockade by low concentrations of oligomeric Aβ 1-42 (Liu et al. 2009 ). In complete contrast to these reports of blockade of various nAChR subtypes by Aβ 1-42 , native presynaptic (Dougherty et al. 2003) or α7 receptors expressed in Xenopus oocytes (Dineley et al. 2002) and native non-α7 nAChRs from acutely dissociated rat basal forebrain neurons were directly activated by Aβ 1-42 peptide (Fu and Jhamandas 2003) .
Desformylflustrabromine (dFBr) is a metabolite of the marine bryozoan Flustra foliacea, commonly found in the North Sea (Lysek et al. 2002) . When the Flustra derivatives (including dFBr) were tested on rat α4β2 and α7 subtypes of nAChRs using radioligand binding assays, it was shown that dFBr had low micromolar affinities for these nAChRs (Peters et al. 2004) . When dFBr was extracted from its natural source and functionally tested on α4β4, α3β2, α3β4, α4β2, and α7 nAChRs expressed in Xenopus oocytes, it potentiated α4β2 receptors but had no effect on the other subtype of nAChRs tested (Sala et al. 2005) . Synthetic dFBr reversibly potentiated ACh-induced α4β2 responses at nanomolar concentrations (pEC 50 =120 nM) and inhibited these responses at micromolar concentrations (IC 50 =150 μM; Kim et al. 2007 ). Synthetic dFBr did not potentiate homomeric α7 receptors, and only inhibition was seen (Kim et al. 2007) . It has been proposed that dFBr potentiates α4β2 receptors by an allosteric mechanism, while its inhibition is via an open-channel block (Weltzin and Schulte 2010) . Furthermore, the effect of dFBr on α2β2 receptors is not known.
In this study, we initially tested whether dFBr potentiates α2β2 receptors and then whether the sensitivity of both α4β2 and α2β2 receptors to Aβ 1-42 is affected by dFBr. We found that dFBr is a positive allosteric modulator (PAM) for both the α2β2 and α4β2 receptors and that dFBr prevents the inhibition of both the α4β2 and α2β2 receptors by Aβ 1-42 .
Methods and Material

RNA Preparation and Expression in Xenopus Oocyte
The mRNAs for rat α2, α4, and β2 nAChR subunits were transcribed in vivo from linearized cDNA using the mMessage Machine kit (Ambion) according to the conditions suggested by the manufacturer. All procedures with Xenopus laevis frogs were approved by the Animal Care and Use Committee of the National Institute of Environmental Health Sciences. Female frogs housed under a 12-h day/night cycle were placed in an ice bath for 15 min and anesthetized by immersion in cold water containing 0.1% ethylmetaaminobenzoate (MS-222; Sigma-Aldrich, St. Louis, MO, USA). Oocytes were dissected and defolliculated by treatment with collagenase B (2 mg/ml; Roche Diagnostics, Indianapolis, IN, USA) and trypsin inhibitor (1 mg/ml; Invitrogen, Carlsbad, CA, USA) for 2 h. The total volume of RNA injected was approximately 50 nl (1 μg/μl). The subunit mRNAs were mixed at a ratio of 1:1 (25 nl of each was injected).
Oocyte Electrophysiology Current responses were obtained by two-electrode voltage clamp recording at a holding potential of −60 mV using a Geneclamp 500 amplifier and pClamp 8 software (Molecular Devices, Sunnyvale CA, USA). All electrophysiological experiments were done at room temp (∼24°C). Electrodes contained 3 M KCl and had a resistance of <1 MΩ. The oocytes were continuously perfused with bath solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES). Drugs were applied using a synthetic quartz perfusion tube (0.7 mm i.d.) operated by a computercontrolled valve for 3 to 4 s. Drugs were applied at an interval of 4 to 5 min. The peak amplitude with 100 μM ACh was obtained for each oocyte, and all responses were normalized to responses obtained at this concentration.
Chemicals and Solutions
Aβ 1-42 peptide was purchased from Anaspec (Fremont, CA, USA) and reconstituted in basic buffer (1% NH 4 OH). The stock solution of Aβ 1-42 peptide was diluted fresh in bath solution daily. Acetylcholine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Desformylflustrabromine was purchased from Tocris, Inc. (Ellisville, MO, USA), and stock solutions were diluted directly in the bath solution.
Data Analysis and Statistical Procedures
Concentration-response curves were fit by non-linear curve fitting in GraphPad Prism Software (San Diego, CA, USA) using standard built-in algorithms. For obtaining the potentiation/inhibition curve for α2β2 receptor modulation by dFBr, the data were fit to a bell-shaped dose-response equation (in GraphPad) as was done previously for the potentiation of α4β2 receptor by dFBr (Kim et al. 2007 ). This equation simultaneously fits both the potentiation and inhibition phases to give an EC 50 for the potentiation component and an IC 50 for the inhibitory component. For determining the EC 50 value for ACh, the data were fit to the Hill equation:
where I is the current at a given agonist concentration, I max is the maximal current obtained at a saturating agonist (ACh) concentration, EC 50 is the agonist concentration that elicits a half-maximal current, A is the agonist, and n is the Hill coefficient. The percent response and inhibition was calculated from the averaged data expressed as mean±SE. GraphPad Prism Software (San Diego, CA, USA) was also used to measure associations between the variables and assess statistical significance using the two-tailed paired t test. All statistical differences were deemed significant at the level of p < 0.05.
Results
dFBr Potentiates α2β2 Receptors
Initially we tested whether dFBr has any effect on α2β2 nAChRs, since dFBr has previously been tested only on the α3β2, α3β4, α4β2, α4β4, and the α7 subtypes. In Xenopus oocytes expressing α2β2 receptors, dFBr on its own failed to elicit any currents (data not shown) in oocytes clamped at holding potential of −60 mV. When dFBr was co-applied with 100 μM ACh, it potentiated the AChinduced currents by 127±18% (n=4; Fig. 1a, left traces) . At higher concentrations, dFBr inhibited the ACh-induced responses (Fig. 1a, right traces) . The dose-response curve of dFBr at varying concentrations is shown in Fig. 1b . The concentration of dFBr inducing half-maximal potentiation was 446±124 nM, and the concentration causing halfmaximal inhibition was 11.3±2.3 μM. The extent of the potentiation is similar to that observed previously for α4β2 receptors (Sala et al. 2005) . Fig. 1 Effects of dFBr on α2β2 receptors. a In Xenopus oocytes expressing rat α2β2 receptors voltage-clamped to −60 mV, 100 μM ACh induces inward current responses that are potentiated by the coapplication (with ACh) of 1 μM dFBr (left two traces). Co-applying a higher dose of dFBr (100 μM) with ACh inhibited the amplitude of ACh responses (right two traces). The time of drug exposure is indicated by the horizontal bar above the traces. b Dose-response curve for varying concentrations of dFBr applied in the presence of 100 μM ACh. The peak amplitudes were normalized to peak currents obtained from 100 μM ACh in the absence of dFBr. c ACh doseresponse curves in the absence (circle) and presence (square) of dFBr (1 μM). The vertical dotted lines from the two curves correspond to the EC 50 value of ACh with and without dFBr. Responses were obtained using two-electrode voltage clamp on Xenopus oocytes expressing rat α2β2 receptors. Peak amplitudes were normalized to peak currents obtained with 100 μM ACh in the absence of dFBr. Amplitudes are expressed as mean±SE; n=4 for each data point A comparison of ACh dose-response curves in the presence and absence of 1 μM dFBr (Fig. 1c) indicates that dFBr causes a decrease in the apparent EC 50 value of ACh from 50.3 ± 3.8 to 18.2 ± 2.3 μM. Therefore, the presence of dFBr (1 μM) leads to an increase in the apparent affinity of ACh for the α2β2 receptors, along with an increase in the amplitude of the maximal response. Fig. 2 Effect of dFBr on inhibition of α2β2 receptors by Aβ 1-42 . a In oocytes expressing α2β2 receptors, the peak amplitude of ACh (100 μM)-induced responses is reduced by the coapplication with 1 μM Aβ 1-42 (left two traces). When the AChinduced responses have been potentiated with dFBr (1 μM), co-application with Aβ 1-42 now has no effect on the amplitude of the responses (right two traces). b Normalized amplitudes of ACh-induced responses; 1 μM Aβ 1-42 significantly inhibited ACh responses in the absence of dFBr (p=0.0166; n=8), but not in its presence (p=0.1120; n=8). c Percent inhibition of ACh responses by Aβ 1-42 in absence (left) and presence of dFBr (right); the difference was significant (p=0.0066; n=8). Asterisk indicates significant difference Fig. 3 Effect of dFBr on inhibition of α4β2 receptors by Aβ 1-42 . a In oocytes expressing α4β2 receptors, the peak amplitude of ACh (100 μM)-induced responses is reduced by the coapplication with 1 μM Aβ 1-42 (left two traces). When the AChinduced responses have been potentiated with dFBr (1 μM), co-application with Aβ 1-42 now has no effect on the amplitude of the responses (right two traces). b Normalized amplitudes of ACh-induced responses; 1 μM Aβ 1-42 significantly inhibited ACh responses in the absence of dFBr (p=0.0118; n=5), but not in its presence (p=0.5718; n=5). c Percent inhibition of ACh responses by Aβ 1-42 in absence (left) and presence of dFBr (right); the difference was significant (p=0.0201; n=5). Asterisk indicates significant difference Action of dFBr on Inhibition of α2β2 Receptors by Aβ Previously, we have shown that 1 μM Aβ 1-42 inhibits carbachol-induced currents in Xenopus oocytes expressing α2β2 receptors (Lamb et al. 2005) . We studied the effect of dFBr on inhibition of α2β2 receptors by Aβ 1-42 . When 1 μM Aβ 1-42 was co-applied with 100 μM ACh, the average response amplitude obtained was 77.5 ±6.9% (n = 8) of that obtained by 100 μM ACh alone (Fig. 2) ; the peak amplitudes of ACh responses were significantly decreased with 1 μM Aβ 1-42 by 22.4 ± 6.8% (n =8; Fig. 2 ; p = 0.0166). In oocytes where the α2β2 receptor-mediated responses were potentiated by 1 μM dFBr, co-application with 1 μM Aβ 1-42 now had no significant effect on the response amplitude (Fig. 2) . The response amplitude increased slightly by 3.43 ± 2.3% (n = 8) in the presence of Aβ 1-42 , which was not significantly different from the response amplitude obtained with ACh and dFBr alone ( Fig. 2 ; p = 0.1120). Therefore, the presence of dFBr appeared to block the inhibition of the α2β2 receptors by Aβ 1-42 .
Action of dFBr on Inhibition of α4β2 Receptors by Aβ For α4β2 receptors expressed in Xenopus oocytes, co-application of 1 μM Aβ 1-42 with 100 μM ACh resulted in average response amplitudes that were 85.2±3.3% of that obtained by 100 μM ACh alone (Fig. 3) . The peak amplitudes were significantly decreased with 1 μM Aβ 1-42 by 16.9±3.8% (n=5; Fig. 3 ; p=0.0118). In oocytes where the α4β2 receptor-mediated responses were potentiated by 1 μM dFBr, co-application with 1 μM Aβ 1-42 now had no significant effect on the response amplitude (Fig. 3) . The response amplitude decreased slightly by 2.02 ± 2.4% (n=5), which was not significantly different from the response amplitude obtained with ACh and dFBr alone ( Fig. 3; p=0.5718) . Therefore, as with the α2β2 receptors, the presence of dFBr appeared to block the inhibition of the α4β2 receptors by Aβ 1-42 .
Discussion
Previously, dFBr had been identified as a positive allosteric modulator for the α4β2 receptors; however, it had no effect on other nAChR subtypes such as the α3β2, α3β4, α4β2, α4β4, and the α7 subtypes (Sala et al. 2005) . Therefore, we initially tested the action of dFBr on rat α2β2 nAChRs as this was not previously examined. For α2β2 nAChRs expressed in Xenopus oocytes, dFBr, at lower concentrations, potentiated ACh-induced responses to a similar extent as for the α4β2 receptors. In addition, we observed that higher doses of dFBr decreased the amplitude of the α2β2, similar to what was previously observed for the α4β2 receptor (Kim et al. 2007 ). The decline in amplitude of the ACh-induced responses with dFBr on α2β2 receptor is consistent with an open-channel block mechanism suggested for the α4β2 receptors (Weltzin and Schulte 2010) .
Furthermore, the ACh dose-response curves in the presence and absence of dFBr shows that dFBr increases the apparent affinity and efficacy of ACh for α2β2 receptors. This increase in apparent efficacy and affinity suggests that the potentiating effect of dFBr is due to its binding to a distinct site separate from the agonist binding site as has been proposed for PAMs for the α7 nAChRs (Young et al. 2008) .
Previously, we have reported that Aβ 1-42 inhibited various subtypes of the non-α7 nAChRs expressed in oocytes, including the α2β2 and α4β2 receptors, but not the α7 nAChRs (Lamb et al. 2005) . These receptors are known to be expressed in rat CA1 hippocampal interneurons (McQuiston and Madison 1999; Sudweeks and Yakel 2000; Yakel and Shao 2004) , and it is well-known that the non-α7 nAChRs have a positive role in regulating cognitive function (Picciotto et al. 1995; Levin and Simon 1998) . Therefore, inhibition of these receptors (e.g., with Aβ 1-42 ) could lead to impairment in cognitive function. Furthermore, there is considerable decline in the number of nAChRs (especially the α4 subunit-containing receptors) in patients suffering from AD (Paterson and Nordberg 2000; Court et al. 2001 ). Here we have found that the inhibition of the α4β2 and α2β2 receptors by Aβ 1-42 is blocked by the presence of dFBr. While the mechanism of inhibition of these receptors by Aβ 1-42 is unknown, as is the mechanism whereby dFBr blocks this action, it is possible that dFBr and similar compounds might have positive effects on cognitive function in patients with AD in part through these actions. Further studies will directly address these issues.
In conclusion, we have demonstrated that dFBr is a PAM for both α4β2 and α2β2 nAChRs and that it interferes with the inhibitory actions of Aβ 1-42 on these receptors. Therefore, the nAChR-specific PAMs may be a clinically useful tool in combating the inhibition of these receptors by Aβ 1-42 in patients suffering with AD by the restoring the cholinergic tone.
